Verisante Technology, Inc. announced that it has entered into an agreement that amends the licensing agreement originally entered into with the BC Cancer Agency in July 2010. Under the more favorable terms of the Agreement, the company continues to hold exclusive rights to use and sublicense BCCA's patented Raman technology, and to manufacture and sell Aura, a device for the detection of skin cancer, and Core, a device for the detection of certain internal cancers in specified territories.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.005 USD | +117.39% |
|
0.00% | +49,900.00% |
1st Jan change | Capi. | |
---|---|---|
+49,900.00% | 220K | |
+3.26% | 209B | |
+6.55% | 183B | |
+31.66% | 158B | |
+34.32% | 114B | |
+5.13% | 67.29B | |
+19.33% | 54.83B | |
-3.30% | 46.88B | |
-4.84% | 38.58B | |
+3.83% | 36.65B |
- Stock Market
- Equities
- VRSEF Stock
- News Verisante Technology Inc.
- Verisante Technology, Inc. Enters Amended Licensing Agreement with the BC Cancer Agency